阿尔茨海默病中的手性:系统性审查
Giorgio Guido1, Alberto Bonato2, Samuele Bonomi3
1Department of Biomedical and Biotechnological Sciences, University of Catania, Catania.
Alzheimer disease and associated disorders
|August 23, 2024
概括
左撇子不是晚期阿尔茨海默病 (AD) 的风险因素. 然而,非右撇子在早期发病的阿尔茨海默病患者中更为常见,而右撇子不会影响认知表现.
科学领域:
- 神经科学是一个神经科学.
- 临床神经学 临床神经学
背景情况:
- 手性研究是有限的,关于它与阿尔茨海默病 (AD) 的联系存在误解.
- 了解阿尔茨海默病的手性对疾病发病和患者管理至关重要.
研究的目的:
- 系统地审查手性与阿尔茨海默病 (AD) 之间的联系.
- 调查手性是否会影响阿兹海默症患者的认知表现.
主要方法:
- 使用PubMed,Embase和Cochrane图书馆进行了系统的文献搜索,遵循PRISMA指南.
- 分析中包括了12篇文章,调查了手性和AD之间的联系.
主要成果:
- 左撇子不是晚期发作的AD (LOAD) 的风险因素.
- 非右撇子在早期发病的AD (EOAD) 病例中患病率更高.
- 手性没有显著影响AD患者的神经心理表现.
结论:
- 手性与AD亚型 (EOAD与LOAD) 之间的关联需要进一步调查.
- 澄清手性-AD联系可能会改善康复策略和临床试验的患者分层.
- 未来的研究应该考虑区分混合和左撇子,以获得更精确的结果.
更多相关视频
07:06Block Building Task Identifies Distinct Groups of Left/Right-hand Choice Patterns After Unilateral Peripheral Nerve Injury
Published on: March 21, 2025
455
08:29Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
14.0K
相关概念视频
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Lateralization
317
Brain lateralization refers to the division of mental processes and functions between the two hemispheres of the brain, a phenomenon that optimizes neural efficiency and underpins complex abilities in humans. This specialization allows each hemisphere to perform tasks where it has a comparative advantage, facilitating more refined cognitive capabilities across different domains.
317
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
